Morgan Stanley assumed coverage of Zimmer Biomet (ZBH) with an Equal Weight rating and a price target of $115, down from $122. The firm says Zimmer has “decent product cycles,” but argues that the current valuation is “largely appropriate.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet receives FDA approval for Oxford Cementless Partial Knee
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Zimmer Biomet announces CE Mark certification for knee system
- Zimmer Biomet names Arnold Schwarzenegger as Chief Movement Officer
- Zimmer Biomet price target raised to $125 from $120 at RBC Capital